| Stacey L Bean, PA-C | |
|
1501 E 10th St, Atlantic, IA 50022-1936 | |
| (712) 243-2850 | |
| (712) 243-7423 |
| Full Name | Stacey L Bean |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 30 Years |
| Location | 1501 E 10th St, Atlantic, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831283092 | NPI | - | NPPES |
| 3032763 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AM0700X | Physician Assistant - Medical | 001688 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carroll Area Nursing Services | Carroll, IA | Home health agency |
| Cass County Memorial Hospital | Atlantic, IA | Hospital |
| Audubon County Memorial Hospital | Audubon, IA | Hospital |
| Exira Care Center | Exira, IA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cass County Memorial Hospital | 5294634994 | 59 |
News Archive
Excelitas Technologies® Corp., a global technology leader delivering innovative, customized photonic solutions, will showcase its X-Cite® Fluorescence Illuminators for Microscopy & Analytical Instrumentation at ABRF (Association of Biomolecular Resource Facilities) 2017 in San Diego, CA.
Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive results from the pivotal trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate targeted to CD30, a defining marker of Hodgkin lymphoma.
Today, the U.S. Food and Drug Administration approved Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the E. coli-derived asparaginase products used most commonly for treatment.
Women with pedometers and a goal of 10,000 steps per day walked more than those whose goal was a brisk, 30-minute walk, according to new research published in the April issue of Medicine & Science in Sports & Exercise®, the official journal of the American College of Sports Medicine (ACSM).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stacey L Bean, PA-C 1501 E 10th St, Atlantic, IA 50022-1936 Ph: (712) 243-2850 | Stacey L Bean, PA-C 1501 E 10th St, Atlantic, IA 50022-1936 Ph: (712) 243-2850 |
News Archive
Excelitas Technologies® Corp., a global technology leader delivering innovative, customized photonic solutions, will showcase its X-Cite® Fluorescence Illuminators for Microscopy & Analytical Instrumentation at ABRF (Association of Biomolecular Resource Facilities) 2017 in San Diego, CA.
Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive results from the pivotal trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate targeted to CD30, a defining marker of Hodgkin lymphoma.
Today, the U.S. Food and Drug Administration approved Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the E. coli-derived asparaginase products used most commonly for treatment.
Women with pedometers and a goal of 10,000 steps per day walked more than those whose goal was a brisk, 30-minute walk, according to new research published in the April issue of Medicine & Science in Sports & Exercise®, the official journal of the American College of Sports Medicine (ACSM).
› Verified 3 days ago
Mrs. Mary K Robinson, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1501 E 10th St, Atlantic, IA 50022 Phone: 712-243-2850 Fax: 712-243-7423 | |
George M Starlin, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1501 E 10th St, Atlantic, IA 50022 Phone: 712-243-2850 Fax: 712-243-7423 | |
Samantha Rose Schuster, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 1300 E 19th St, Atlantic, IA 50022 Phone: 737-226-6700 Fax: 877-384-3106 | |
Mr. Scott Alan Hixson, MPAS, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1501 E 10th St, Atlantic, IA 50022 Phone: 712-243-2850 Fax: 712-243-7423 |